Zemvax Appoints Gong Kyung-sun as Vice President... "Clinical Expert"

Gong Kyung-sun, new Vice President of ZEMVAX & KAEL (Photo by ZEMVAX & KAEL)

[Asia Economy Reporter Chunhee Lee] GemVax & Kael announced on the 1st that it has recruited Kyung-sun Gong, a clinical expert and former CEO of DreamCIS, as its vice president.

New Vice President Kyung-sun Gong began her career at Samsung Medical Center's Cancer Center and has held positions such as clinical development director at the International Vaccine Institute, Korea Wires, Crystal Genomics, Parexel, and Yuhan Corporation, before serving as CEO of DreamCIS. She is an expert with 27 years of diverse experience in clinical settings and has recently led all clinical trial operations, including clinical and post-marketing surveillance (PMS) and other related tasks, as CEO of DreamCIS, a specialized clinical research organization (CRO).

GemVax plans to accelerate clinical trials in the US, Europe, and Korea by recruiting Vice President Gong, who has extensive clinical experience.

Vice President Gong stated, “GemVax, which has embarked on full-scale global clinical trials, is at a point where the role of a professional clinical manager is more important than ever. Based on my experience, I will devote all my capabilities to ensure that the Alzheimer's disease clinical trials conducted in Korea, the US, and seven European countries proceed quickly and accurately.”

GemVax is conducting Phase 2 clinical trials of 'GV1001,' being developed as a treatment for Alzheimer's dementia, targeting patients with mild to moderate Alzheimer's disease simultaneously in the US and seven European countries (Spain, France, Italy, Portugal, the Netherlands, Poland, and Finland). The Investigational New Drug (IND) application has been approved in the US and Spain.

This content was produced with the assistance of AI translation services.